Cellphire Therapeutics focus is to save lives by bringing novel hemostatic products to patients most in need. Our initial product candidates have substantial advantages compared to the current standard of care, liquid stored platelets, which are subject to challenges in availability (due to short shelf life of 3-5 days), efficacy and safety:
Cellphire currently has two differentiated products in Phase 2 clinical studies, our freeze-dried platelet-derived hemostat "FPH" (Thrombosomes®), and our Cryopreserved Platelets "CPP".
About our scienceCellphire is actively recruiting study sites for our Phase 2 clinical trial.
We are continually exploring new applications for stabilized cellular therapies.